Tyche Wealth Partners LLC Buys 50,864 Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS)

Tyche Wealth Partners LLC grew its stake in Coherus BioSciences, Inc. (NASDAQ:CHRS) by 23.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 266,766 shares of the biotechnology company’s stock after acquiring an additional 50,864 shares during the quarter. Tyche Wealth Partners LLC owned 0.23% of Coherus BioSciences worth $368,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of CHRS. Systematic Financial Management LP bought a new stake in Coherus BioSciences in the third quarter valued at approximately $28,000. Steph & Co. bought a new stake in shares of Coherus BioSciences in the 4th quarter valued at $34,000. FMR LLC raised its stake in Coherus BioSciences by 21.1% during the 3rd quarter. FMR LLC now owns 225,113 shares of the biotechnology company’s stock worth $234,000 after buying an additional 39,204 shares during the period. XTX Topco Ltd raised its stake in Coherus BioSciences by 74.5% during the 3rd quarter. XTX Topco Ltd now owns 473,517 shares of the biotechnology company’s stock worth $492,000 after buying an additional 202,084 shares during the period. Finally, Los Angeles Capital Management LLC lifted its holdings in Coherus BioSciences by 344.1% during the third quarter. Los Angeles Capital Management LLC now owns 930,132 shares of the biotechnology company’s stock worth $967,000 after acquiring an additional 720,672 shares in the last quarter. 72.82% of the stock is currently owned by institutional investors and hedge funds.

Coherus BioSciences Stock Performance

NASDAQ CHRS opened at $1.13 on Friday. Coherus BioSciences, Inc. has a 52 week low of $0.66 and a 52 week high of $2.87. The stock’s 50 day moving average price is $1.44 and its two-hundred day moving average price is $1.24. The stock has a market capitalization of $130.96 million, a price-to-earnings ratio of -14.13 and a beta of 0.81.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Coherus BioSciences in a research report on Thursday, January 23rd. StockNews.com lowered shares of Coherus BioSciences from a “buy” rating to a “hold” rating in a research note on Saturday, October 19th. Finally, Robert W. Baird increased their price objective on shares of Coherus BioSciences from $4.00 to $6.00 and gave the stock an “outperform” rating in a research report on Thursday, December 5th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, Coherus BioSciences presently has an average rating of “Moderate Buy” and an average target price of $5.38.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.